Invokana (in-vo-KAHN-uh, canagliflozin), the first in a new class of oral drugs for type 2 diabetes

Reps will promote Invokana (in-vo-KAHN-uh, canagliflozin), the first in a new class of oral drugs for type 2 diabetes.

You'll hear it referred to as an "SGLT2 inhibitor"...because it inhibits sodium-glucose co-transporter 2 in the kidneys. This allows more glucose to spill into the urine instead of being reabsorbed.

Reps will point out that Invokana reduces A1C by 1% when used alone...and it has a low risk of hypoglycemia.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote